| Dr Annette N Anderson, MD | |
|
495 Hogan Ln Ste 2, Conway, AR 72034-8498 | |
| (501) 358-6695 | |
| (501) 358-6860 |
| Full Name | Dr Annette N Anderson |
|---|---|
| Gender | Female |
| Speciality | Geriatric Psychiatry |
| Experience | 20 Years |
| Location | 495 Hogan Ln Ste 2, Conway, Arkansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811170301 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0805X | Psychiatry & Neurology - Geriatric Psychiatry | E-5622 (Arkansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Conway Regional Health System | Conway, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Conway Regional Medical Center Inc | 3173428414 | 127 |
News Archive
Oxford Gene Technology (OGT), The Molecular Genetics Company, has developed a new range of non-human fluorescence in situ hybridisation (FISH) probes, for pig, chicken and mouse. The probes were developed as part of an Innovate UK knowledge transfer partnership (KTP) funded project in collaboration with the University of Kent, and was given an ‘outstanding' award reserved for the top 10% of KTP projects.
Researchers have gained new insight into why 22% of Canadian women of childbearing age are still not achieving a folate concentration considered optimal for reducing the risk of having babies with neural tube defects, despite a virtual absence of folate deficiency in the general Canadian population.
Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company has been selected to present key efficacy data at the upcoming American Academy of Neurology (AAN) 62nd Annual Meeting to be held in Toronto, Canada.
Registration to the 21st edition of Diabetes UK's Professional Conference is now open, with the conference set to take place from Wednesday 6 March to Friday 8 March of next year at the Arena and Convention Centre Liverpool.
› Verified 5 days ago
| Entity Name | Conway Regional Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417024662 PECOS PAC ID: 3173428414 Enrollment ID: O20050825001031 |
News Archive
Oxford Gene Technology (OGT), The Molecular Genetics Company, has developed a new range of non-human fluorescence in situ hybridisation (FISH) probes, for pig, chicken and mouse. The probes were developed as part of an Innovate UK knowledge transfer partnership (KTP) funded project in collaboration with the University of Kent, and was given an ‘outstanding' award reserved for the top 10% of KTP projects.
Researchers have gained new insight into why 22% of Canadian women of childbearing age are still not achieving a folate concentration considered optimal for reducing the risk of having babies with neural tube defects, despite a virtual absence of folate deficiency in the general Canadian population.
Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company has been selected to present key efficacy data at the upcoming American Academy of Neurology (AAN) 62nd Annual Meeting to be held in Toronto, Canada.
Registration to the 21st edition of Diabetes UK's Professional Conference is now open, with the conference set to take place from Wednesday 6 March to Friday 8 March of next year at the Arena and Convention Centre Liverpool.
› Verified 5 days ago
| Entity Name | Conway Regional Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730402249 PECOS PAC ID: 3173428414 Enrollment ID: O20200527001733 |
News Archive
Oxford Gene Technology (OGT), The Molecular Genetics Company, has developed a new range of non-human fluorescence in situ hybridisation (FISH) probes, for pig, chicken and mouse. The probes were developed as part of an Innovate UK knowledge transfer partnership (KTP) funded project in collaboration with the University of Kent, and was given an ‘outstanding' award reserved for the top 10% of KTP projects.
Researchers have gained new insight into why 22% of Canadian women of childbearing age are still not achieving a folate concentration considered optimal for reducing the risk of having babies with neural tube defects, despite a virtual absence of folate deficiency in the general Canadian population.
Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company has been selected to present key efficacy data at the upcoming American Academy of Neurology (AAN) 62nd Annual Meeting to be held in Toronto, Canada.
Registration to the 21st edition of Diabetes UK's Professional Conference is now open, with the conference set to take place from Wednesday 6 March to Friday 8 March of next year at the Arena and Convention Centre Liverpool.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Annette N Anderson, MD Po Box 9662, Conway, AR 72033-9662 Ph: (501) 358-6695 | Dr Annette N Anderson, MD 495 Hogan Ln Ste 2, Conway, AR 72034-8498 Ph: (501) 358-6695 |
News Archive
Oxford Gene Technology (OGT), The Molecular Genetics Company, has developed a new range of non-human fluorescence in situ hybridisation (FISH) probes, for pig, chicken and mouse. The probes were developed as part of an Innovate UK knowledge transfer partnership (KTP) funded project in collaboration with the University of Kent, and was given an ‘outstanding' award reserved for the top 10% of KTP projects.
Researchers have gained new insight into why 22% of Canadian women of childbearing age are still not achieving a folate concentration considered optimal for reducing the risk of having babies with neural tube defects, despite a virtual absence of folate deficiency in the general Canadian population.
Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company has been selected to present key efficacy data at the upcoming American Academy of Neurology (AAN) 62nd Annual Meeting to be held in Toronto, Canada.
Registration to the 21st edition of Diabetes UK's Professional Conference is now open, with the conference set to take place from Wednesday 6 March to Friday 8 March of next year at the Arena and Convention Centre Liverpool.
› Verified 5 days ago
Douglas G Callahan, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 350 Salem Road, Ste 1, Conway, AR 72034 Phone: 501-336-8300 Fax: 501-329-3572 | |
Dr. Keith O Schluterman, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2200 Ada Ave Ste 302, Conway, AR 72034 Phone: 501-932-0352 Fax: 501-932-0354 | |
Asim Raza, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 350 Salem Road, Ste 1, Conway, AR 72034 Phone: 501-336-8300 Fax: 501-329-3572 | |
Dr. Timothy E Freyaldenhoven, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2200 Ada Ave Ste 302, Conway, AR 72034 Phone: 501-932-0352 Fax: 501-932-0354 | |
Dr. David E. Anderson, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2525 College Ave, Conway, AR 72034 Phone: 501-712-1998 Fax: 501-712-1999 | |
Atif M Akhtar, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 350 Salem Rd Ste 1, Conway, AR 72034 Phone: 501-336-8300 Fax: 501-329-5508 | |
Lauren Davis, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2215 E Oak St Ste 1, Conway, AR 72032 Phone: 501-336-0511 Fax: 501-336-4037 |